Desentum Oy
Imagine a world without allergies
Finland
9 employees
Venture round
Total: $27.75M
Biotechnology, Pharmaceutical
General Information
Finland
BounceWatch is an independent company data service, not affiliated with Desentum Oy. To contact Desentum Oy, visit desentum.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
Finland Market
Biotechnology
About Desentum Oy
Taxonomy: biopharmaceutical, allergy vaccines, immunotherapy, clinical-stage, research-oriented, hypersensitivity reaction, molecular mechanism, allergic symptoms, tolerance, long-term relief, economic burden, allergens, immunotherapy products, novel vaccine development, allergy treatment
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | €12.00M | 1 |
|
08 Feb 2024 |
| Venture Round | €8.00M | 1 |
|
21 Jan 2022 |
| Venture Round | €4.00M | - |
|
01 Nov 2019 |
| Grant | €1.90M | 1 |
|
30 Oct 2018 |
| Series A | Undisclosed | 1 |
|
15 Nov 2017 |
| Series A | €1.85M | 4 |
|
23 Jan 2017 |
Desentum Oy Alternatives & Competitors
View All Alternatives
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel va...
Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzym...
Innovating patient compliance with solid dose therapeutics and vaccines for long-term health.
FAQ About Desentum Oy
Source: BounceWatch company record for Desentum Oy, https://bouncewatch.com/company/desentum, updated 24 October 2024. When citing, please name BounceWatch and link this page.
